New research conducted in Sweden indicates that genetic testing may help identify breast cancer patients at risk of developing venous thromboembolism while undergoing chemotherapy. According to study author Judith Brand, postdoctoral researcher in the department of medical epidemiology and biostatistics at Karolinska Institute in Sweden, the study, conducted on 4,2000 Swedish women with breast cancer showed that "the one-year rate of venous thromboembolism was 9.5% among those reeving chemotherapy and high genetic risk, compared to 1.3% of did not receive chemotherapy and who had a low genetic risk.
To read more about this study, click here.
No comments:
Post a Comment